Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital.
5' Untranslated Regions
Base Sequence
Commerce
Genomics
/ methods
Genotype
Genotyping Techniques
/ economics
Hepacivirus
/ genetics
Hepatitis C
/ diagnosis
Humans
Molecular Probe Techniques
/ economics
Phylogeny
RNA, Viral
/ analysis
Reagent Kits, Diagnostic
/ economics
Retrospective Studies
Sequence Analysis, RNA
/ economics
Tertiary Care Centers
Genotyping
Hepatitis C virus
Sequencing
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
22 Aug 2019
22 Aug 2019
Historique:
received:
03
09
2018
accepted:
15
08
2019
entrez:
24
8
2019
pubmed:
24
8
2019
medline:
28
10
2019
Statut:
epublish
Résumé
The technique most frequently used to genotype HCV is quantitative RT-PCR. This technique is unable to provide an accurate genotype/subtype for many samples; we decided to develop an in-house method with the goal of accurately identifying the genotype of all samples. As a Belgium National Centre of reference for hepatitis, we developed in-house sequencing not only for 5'UTR and core regions starting from VERSANT LiPA amplicons but also for NS5B regions. The sequencing of VERSANT LiPA amplicons might be useful for many laboratories worldwide using the VERSANT LiPA assay to overcome undetermined results. 100 samples from Hepatitis C virus infected patients analysed by the VERSANT HCV Genotype 2.0 LiPA Assay covering frequent HCV types and subtypes were included in this study. NS5B, 5'UTR and Core home-made sequencing were then performed on these samples. The sequences obtained were compared with the HCV genomic BLAST bank. All the samples were characterised by the VERSANT LiPA assay (8 G1a, 17 G1b, 6 G2, 11 G3, 13 G4, and 10 G6). It was not possible to discriminate between G6 and G1 by the VERSANT LiPA assay for 8 samples and 27 had an undetermined genotype. Forty-one samples were sequenced for the three regions: NS5B, 5'UTR and Core. Twenty-three samples were sequenced for two regions: 5' UTR and Core and 36 samples were sequenced only for NS5B. Of the 100 samples included, 64 samples were analysed for 5'UTR and Core sequencing and 79 samples were analysed for NS5B sequencing. The global agreement between VERSANT LiPA assay and sequencing was greater than 95%. In this study, we describe a new, original method to confirm HCV genotypes of samples not discriminated by a commercial assay, using amplicons already obtained by the screening method, here the VERSANT LiPA assay. This method thus saves one step if a confirmation assay is needed and might be of usefulness for many laboratories worldwide performing VERSANT LiPA assay in particular.
Sections du résumé
BACKGROUND
BACKGROUND
The technique most frequently used to genotype HCV is quantitative RT-PCR. This technique is unable to provide an accurate genotype/subtype for many samples; we decided to develop an in-house method with the goal of accurately identifying the genotype of all samples. As a Belgium National Centre of reference for hepatitis, we developed in-house sequencing not only for 5'UTR and core regions starting from VERSANT LiPA amplicons but also for NS5B regions. The sequencing of VERSANT LiPA amplicons might be useful for many laboratories worldwide using the VERSANT LiPA assay to overcome undetermined results.
METHODS
METHODS
100 samples from Hepatitis C virus infected patients analysed by the VERSANT HCV Genotype 2.0 LiPA Assay covering frequent HCV types and subtypes were included in this study. NS5B, 5'UTR and Core home-made sequencing were then performed on these samples. The sequences obtained were compared with the HCV genomic BLAST bank.
RESULTS
RESULTS
All the samples were characterised by the VERSANT LiPA assay (8 G1a, 17 G1b, 6 G2, 11 G3, 13 G4, and 10 G6). It was not possible to discriminate between G6 and G1 by the VERSANT LiPA assay for 8 samples and 27 had an undetermined genotype. Forty-one samples were sequenced for the three regions: NS5B, 5'UTR and Core. Twenty-three samples were sequenced for two regions: 5' UTR and Core and 36 samples were sequenced only for NS5B. Of the 100 samples included, 64 samples were analysed for 5'UTR and Core sequencing and 79 samples were analysed for NS5B sequencing. The global agreement between VERSANT LiPA assay and sequencing was greater than 95%.
CONCLUSIONS
CONCLUSIONS
In this study, we describe a new, original method to confirm HCV genotypes of samples not discriminated by a commercial assay, using amplicons already obtained by the screening method, here the VERSANT LiPA assay. This method thus saves one step if a confirmation assay is needed and might be of usefulness for many laboratories worldwide performing VERSANT LiPA assay in particular.
Identifiants
pubmed: 31438880
doi: 10.1186/s12879-019-4386-4
pii: 10.1186/s12879-019-4386-4
pmc: PMC6704641
doi:
Substances chimiques
5' Untranslated Regions
0
RNA, Viral
0
Reagent Kits, Diagnostic
0
Types de publication
Comparative Study
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
738Références
Syst Biol. 2006 Aug;55(4):539-52
pubmed: 16785212
J Clin Microbiol. 2006 Nov;44(11):3969-74
pubmed: 16957039
J Clin Microbiol. 2008 Jun;46(6):1901-6
pubmed: 18400913
PLoS One. 2009 Dec 08;4(12):e8209
pubmed: 19997618
Syst Biol. 2010 May;59(3):307-21
pubmed: 20525638
J Hepatol. 2011 Aug;55(2):245-64
pubmed: 21371579
Int J Mol Med. 2013 Feb;31(2):347-52
pubmed: 23241873
J Clin Virol. 2013 Sep;58(1):249-53
pubmed: 23731847
Hepatology. 2014 Jan;59(1):318-27
pubmed: 24115039
J Viral Hepat. 2014 Apr;21(4):229-40
pubmed: 24597691
J Clin Virol. 2014 May;60(1):22-6
pubmed: 24656214
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
Hepatology. 2015 Feb;61(2):471-80
pubmed: 25099344
J Clin Microbiol. 2014 Oct;52(10):3685-92
pubmed: 25100817
J Clin Microbiol. 2014 Nov;52(11):4027-9
pubmed: 25143567
J Clin Microbiol. 2015 May;53(5):1754-7
pubmed: 25740780
J Virol Methods. 2015 Oct;223:105-8
pubmed: 26253334
PLoS One. 2016 Apr 20;11(4):e0153754
pubmed: 27097040
Clinicoecon Outcomes Res. 2016 Sep 14;8:467-473
pubmed: 27695353
Liver Int. 2017 Apr;37(4):514-528
pubmed: 28105744
J Virol Methods. 2017 Nov;249:31-37
pubmed: 28851606
Int J Infect Dis. 2018 Feb;67:114-117
pubmed: 29253705
J Med Virol. 2018 May;90(5):942-950
pubmed: 29315640
Diagn Microbiol Infect Dis. 2018 May;91(1):34-37
pubmed: 29434000
PLoS One. 2018 Dec 5;13(12):e0207584
pubmed: 30517127